Asahi Songwon Colors Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹451 Cr
Targeting 15% sales growth over the next 1-2 years (Page 16, Page 12). Targeting 15% top-line (sales) growth over the next 1-2 years.
From Asahi Songwon Colors Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹368
Market Cap
₹451 Cr
P/E Ratio
13.0
How does Asahi Songwon Colors Ltd rank in Chemicals & Petrochemicals?
Compare Asahi Songwon Colors Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Asahi Songwon Colors Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹144 Cr, net profit ₹11 Cr.
Full financials →📊 Revenue & Sales Performance
- →Targeting 15% sales growth over the next 1-2 years (Page 16, Page 12).
- →Capacity utilization expected to reach 100% over the next two years (Page 20).
- →Maximum top line from current capacity estimated at about ₹750 crores (Page 19).
- →AZO segment capacity utilization to improve from 64% to around 80-85%, with top line growth from ₹70 crores to ₹90 crores (~26-27% growth) (Page 16).
- →API business volumes increased by 25% despite price pressures (Page 7).
- →Overall top line growth expected to be decent, driven by volume and efficiency improvements (Page 12-13).
- →Pigments business growth expected to be modest; blue segment at maximum sustainable capacity with limited growth (Page 18, Page 19).
- →Export share in ATC expected to grow from 10% to 20-25% this year, driving revenue increase (Page 6).
📈 Profitability & Margins
- →Targeting 15% top-line (sales) growth over the next 1-2 years.
- →EBITDA growth expected at around 25%, outperforming sales growth due to capacity utilization improvements and operational efficiencies.
- →Consolidated EBITDA margin targeted at approximately 12%, up from current levels.
- →PBT (Profit Before Tax) growth projected between 50-65% for FY25-26.
- →ROCE (Return on Capital Employed) aimed to improve from around 10-11% to 15% over the next couple of years.
- →Capacity utilization to reach 100% in 1-2 years, supporting top-line growth up to about 750 crores from current capacity.
- →API and AZO segments expected to see EBITDA margin expansion, with AZO EBITDA margin improving from marginally positive to 8-10%.
- →Positive cash flows expected to be used for debt reduction initially, with potential future capex for growth after deleveraging.
🏗️ Capital Expenditure Plans
- →Current capex of about ₹5 crores has been completed, which includes adding about 40 tons to existing yellow pigment capacity with new Chinese equipment (Page 5).
- →No major new capex planned in the short term for existing businesses like pregabalin or AZO; focus will be on utilizing current capacities (Pages 15, 16).
- →Longer-term plans involve possible new CapEx after achieving better utilization and deleveraging (Page 17).
- →Strategy includes launching new API products over the next 1-2 years with backward integration planned for some molecules, but this will be phased and dependent on product success and scale (Pages 9, 11).
- →Tariff opportunities may help scale AZO exports and business, aiding margin improvement, but this does not appear to require significant immediate capex (Pages 6, 16).
💰 Fundraising & Capital Structure
- →The company does not plan any major capex in the near term, which reduces the immediate need for large fundraising.
- →Current strategy focuses on deleveraging by using strong cash generation to retire debt. Total debt equity dropped from 0.75 to 0.55 and is targeted to go below 0.5.
- →EBITDA to debt ratio is improving and likely to drop below 2 in the coming year.
- →Once full capacity utilization and growth materialize over the next 1-2 years, free cash may be deployed for growth capex.
- →No explicit mention of new equity fundraising was made.
- →Overall, short-term focus is on reducing debt and improving cash flow without raising new funds. Longer-term capital raising may be considered when growth and capacity utilization call for significant investments.
📋 Order Book & Pipeline
- →The transcript on page 20 does not explicitly mention the exact current or expected order book value or detailed pending orders.
- →It is indicated that the company has received approvals from a few large export clients and expects to execute at least two large customer orders commercially during the current year.
- →The execution of large orders will be gradual through the upcoming quarters, moving towards commercial large quantity orders by year-end.
- →Capacity utilization is targeted to increase to 100% over the next 1-2 years to support this growth.
- →The expected maximum top-line from current capacity is around ₹750 crores.
- →The AZO segment aims to grow from ₹70 crores to ₹90 crores in revenue this year, with capacity utilization improving to around 80-85%.
Key Metrics
Frequently Asked Questions
What were Asahi Songwon Colors Ltd Q4 FY25 results?
Targeting 15% sales growth over the next 1-2 years (Page 16, Page 12). Targeting 15% top-line (sales) growth over the next 1-2 years.
What is Asahi Songwon Colors Ltd share price analysis?
Asahi Songwon Colors Ltd currently shows a neutral. The stock trades at a P/E of 13.0 with a market cap of ₹451 Cr. Investors should review the full earnings analysis for detailed insights.
Is Asahi Songwon Colors Ltd planning capital expenditure?
Current capex of about ₹5 crores has been completed, which includes adding about 40 tons to existing yellow pigment capacity with new Chinese equipment (Page 5).
Keep Asahi Songwon Colors Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.